Arax Advisory Partners’s iRadimed IRMD Stock Holding History

Arax Advisory Partners’s Portfolio IRMD Stock Details IRMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$30K	Sell	312 -39	-11%	-$3.9K	﹤0.01%	1896
2025 Q4	$34.1K	Sell	351 -118	-25%	-$10.1K	﹤0.01%	1826
2025 Q3	$33.4K	Buy	469 +123	+36%	+$8.2K	﹤0.01%	2029
2025 Q2	$20.7K	Sell	346 -14	-4%	-$767	﹤0.01%	1646
2025 Q1	$18.9K	Buy	360 +4	+1%	+$225	﹤0.01%	1323
2024 Q4	$19.6K	Buy	356 +16	+5%	+$842	﹤0.01%	1217
2024 Q3	$17.1K	Buy	340 +231	+212%	+$10.7K	﹤0.01%	1153
2024 Q2	$4.79K	Buy	109 +6	+6%	+$255	﹤0.01%	1615
2024 Q1	$4.53K	Buy	+103	New	+$4.55K	﹤0.01%	923

Other funds holding IRMD

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

CCM

Copeland Capital Management Conshohocken, Pennsylvania $4.5B AUM 18.67% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Kayne Anderson Rudnick Investment Management Los Angeles, California $34B AUM 6.31% 1-Year Est. Return

NTCM

Nine Ten Capital Management Chicago, Illinois $315M AUM 62.95% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Arax Advisory Partners's IRMD Position: Q1 2026 in Review

Arax Advisory Partners reduced its iRadimed (IRMD) stake by 11% in Q1 2026, selling an estimated $3.9K and leaving 312 shares worth $30K. The position accounts for ﹤0.01% of the portfolio, ranked #1896.

Arax Advisory Partners first reported a position in IRMD in Q1 2024 and has held it in 9 quarters since. The position peaked at $34.1K in Q4 2025. 228 funds tracked by Wall St. Rank hold IRMD as of Q1 2026.

Arax Advisory Partners held 312 shares of iRadimed worth $30K as of Q1 2026.
Arax Advisory Partners sold 39 iRadimed shares in Q1 2026, an estimated $3.9K.
iRadimed made up ﹤0.01% of Arax Advisory Partners's portfolio in Q1 2026, its #1896 holding.
Arax Advisory Partners first reported a position in iRadimed in Q1 2024 and has held it in 9 quarters since.
Arax Advisory Partners's iRadimed position peaked at $34.1K in Q4 2025.
228 funds tracked by Wall St. Rank held iRadimed as of Q1 2026.

Based on Arax Advisory Partners's 13F filing for Q1 2026, filed 13 May 2026.